Financials
Value Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26 TTM Selling/general/admin expenses 3.03 B3.42 B3.19 B4.16 B2.96 B 13.72 B Research & development 2.21 B2.48 B3.94 B3.42 B2.63 B 12.46 B Operating income 3.38 B2.08 B1.02 B-1.23 B5.02 B 6.9 B Non-Operating Income, Total 272 M-472 M-82 M-5.2 B-668 M -6.42 B Interest expense, net of interest capitalized 654 M654 M652 M711 M668 M 2.69 B Non-Operating Income, excl. Interest Expenses 571 M-387 M-217 M-1.39 B-475 M -2.47 B Unusual income/expense -953 M-739 M-517 M-4.51 B-861 M -6.63 B Pretax income 2.79 B3.04 B3.33 B-1.64 B3.17 B 7.91 B Equity in earnings ————— — Taxes -189 M141 M-216 M-2 M461 M 384 M Non-controlling/minority interest 6 M18 M9 M8 M8 M 43 M After tax other income/expense -40 M101 M292 M117 M93 M 603 M Net income before discontinued operations 2.97 B2.88 B3.54 B-1.65 B2.7 B 7.48 B Discontinued operations 025 M00-13 M 12 M Net income 2.97 B2.91 B3.54 B-1.65 B2.69 B 7.49 B Dilution adjustment ————— — Preferred dividends ————— — Diluted net income available to common stockholders 2.97 B2.91 B3.54 B-1.65 B2.69 B 7.49 B Basic earnings per share (Basic EPS) 0.520.510.62-0.280.47 1.32 Diluted earnings per share (Diluted EPS) 0.520.510.62-0.290.47 1.31 Average basic shares outstanding 5.67 B5.68 B5.68 B5.68 B5.69 B — Diluted shares outstanding 5.71 B5.71 B5.71 B5.71 B5.73 B — EBITDA 5.29 B3.7 B2.69 B457 M6.64 B 13.48 B EBIT 3.38 B2.08 B1.02 B-1.23 B5.02 B 6.9 B Cost of revenue 2.85 B3.78 B4.17 B5.27 B3.55 B 16.77 B Other cost of goods sold ——33 M-33 M— — Depreciation & amortization (cash flow) 1.62 B1.63 B1.66 B1.69 B1.61 B 6.59 B
News
SELLAS: Imminent Catalyst, Dual-Platform Pipeline, And A Market That Hasn't Caught Up
Here's How Pfizer's Oncology Growth Story Looks Ahead of Q2 Results
Here's What to Expect From Pfizer's Next Earnings Report
Can BMY's CELMoD Program Advancements Strengthen Its Oncology Portfolio?
Pfizer (PFE) Advances While Market Declines: Some Information for Investors
Undercovered Stocks: SK Hynix, Reddit, Austal, Netlist, And More
How To Build A $50,000 Dividend Portfolio In Today's Market
FDA Expands MRK & PFE's Keytruda-Padcev Combo Use in Bladder Cancer
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (July 2026)
Pfizer Stock: The AI Hedge That Pays You To Stay Defensive (NYSE:PFE)
July Graham Value All-Stars (GVAS) Emit 10 Beaming Buys
Charts & Ideas
PFE - Daily Trading Forecast
Daily price was bounced from support level at 25.19 to above for 200 SMA to be crossed for the bullish trend to be resumed. Stochastic oscillator is showing the oversold market condition for the price, and Parabolic SAR is on uptrend for the price to be started so the bullish trend continuation is very likely for D1 price for example. if the price breaks 26.54 resistance level to above for the 27.85 possible target so the primary bullish trend will be resumed; If the price crosses support level at 25.19 to below so the bearish reversal will be started with 24.83 as the target to re-enter; alternatively, the price will be on secondary ranging to be near 200 SMA waiting for the direction of the strong trend to be started. Trading Summary : ranging for direction
1 The PFE doesn’t have other trading ideas at this time
Browse ready-made trading ideas or select a symbol and create your own
Go to Charts and Trading Ideas